Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination

British Journal of Cancer

Volumn 74, Issue 11, 1996, Pages 1828-1833

  Gjertsen, M K ^a   Saeterdal, I ^a   Thorsby, E ^a   Gaudernack, G ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b INSTITUTE OF CANCER RESEARCH   (Norway)

Author keywords

Mutant p21 ras; Pancreatic adenocarcinoma; Peptide vaccination; T cells

Indexed keywords

CANCER VACCINE; HLA DR6 ANTIGEN; PROTEIN P21; RAS PROTEIN;

ARTICLE; CASE REPORT; CLONE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE CLONE; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

EID: 0029825827     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.638     Document Type: Article

References (26)

1. ALMOGUERA C, SHIBATA D, FORRESTER K, MARTIN J, ARNHEIM N AND PERUCHO M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53, 549-554.
2. BOON T, CEROTTINI JC, VAN DEN EYNDE B, VAN DER BRUGGEN P AND VAN PEL A. (1994). Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12, 337-365.
3. CAPELLA G, CRONAUER-MITRA S, PEINADO MA AND PERUCHO M. (1991). Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ. Health Perspectives, 93, 125-131.
4. DER CJ, FINKEL T AND COOPER GM. (1985). Biological and biochemical properties of human ras H genes mutated at codon 61. Cell, 44, 167-176.
5. FOSSUM B, GEDDE-DAHL T III, HANSEN T, ERIKSEN JA, THORSBY E AND GAUDERNACK G. (1993). Overlapping epitopes encompassing a point mutation (12 Gly→Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur. J. Immunol., 23, 2687-2691.
6. + T cells recognize a peptide corresponding to a common mutation (13Gly→Asp). Int. J. Cancer, 56, 40-45.
7. + T cells from a patient with colon carcinoma, specific for a mutant p21 ras derived peptide (13Gly→Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol. Immunother., 40, 165-172.
8. GAUDERNACK G AND LUNDIN KEA. (1989). Rapid immunomagnetic phenotyping of cells. J. Immunogenet., 16, 169-175.
9. GEDDE-DAHL T III, SPURKLAND A, ERIKSEN JA, THORSBY E AND GAUDERNACK G. (1992a). Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln→Leu61). Int. J. Immunol., 4, 1331-1337.
10. GEDDE-DAHL T III, ERIKSEN JA, THORBSY E AND GAUDERNACK G. (1992b). T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Hum. Immunol., 33, 266-274.
11. GEDDE-DAHL T III, FOSSUM B, ERIKSEN JA, THORSBY E AND GAUDERNACK G. (1993). T cell clones specific for p-21 ras-derived peptides: characterization of their fine specificity and HLA restriction. Eur. J. Immunol., 23, 754-760.
12. GEDDE-DAHL T III, SPURKLAND A, FOSSUM B, THORSBY E AND GAUDERNACK G. (1994). T-cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. Eur. J. Immunol., 24, 410-414.
13. GILLIS S, FERM M, OU W AND SMITH KA. (1978). T-cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol., 120, 2027-2032.
14. GJERTSEN MK, BAKKA A, BREIVIK J, SAETERDAL I, SOLHEIM BG, SØREIDE O, THORSBY E AND GAUDERNACK G. (1995). Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet, 346, 1399-1400.
15. GJERTSEN MK, BAKKA A, BREIVIK J, SAETERDAL I, GEDDE-DAHL III T, STOKKE KT, SOLHEIM BJ, EGGE TS, SØREIDE O, THORSBY E AND GAUDERNACK G. (1996). Ex-vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study. Int. J. Cancer, 65, 450-453.
16. JOHANSEN BH, GEDDE-DAHL T III, SOLLID LM, VARTDAL F, THORSBY E AND GAUDERNACK G (1994). Binding of ras oncogene peptides to purified HLA-DQ (alpha 1*0102, beta 1*0602) molecules. Scand. J. Immunol., 39, 607-612.
17. JUNG S AND SCHLUESENER HJ. (1991). Human T lymphocytes recognize a peptide of single point-mutated, oncogene ras proteins. J. Exp. Med., 73, 273-276.
18. KAHN SM, JIANG W, CULBERTSON TA, WEINSTEIN B, WILLIAMS GM, TOMITA N AND RONAI Z. (1991). Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. Oncogene, 6, 1079-1083.
19. MUKHERJI B, CHAKRABORTY NG, YAMASAKI S, OKINO T, YAMASE H, SPORN JR, KURTZMAN SK, ERGIN MT, OZOLS J, MEEHAN J AND MAURI F. (1995). Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl Acad. Sci. USA, 92, 8078-8082.
20. OROSZ CG, ADAMS PW AND FERGUSON RM. (1987). Frequency of human alloantigen-reactive T lymphocytes. Transplantation, 43, 718-724.
21. SEEBURGH PH, COLBY WW, CAPON DJ, GOEDDEL DV AND LEVINSON AD. (1984). Biological properties of human c-HarasI genes mutated at codon 12. Nature, 312, 71-75.
22. SKIPPER J AND STAUSS HJ. (1993). Identification of two cytotoxic T lymphocyte-recognized epitopes in the ras protein. J. Exp. Med., 177, 1493-1498.
23. SLAMON DJ, deKERNION JB, VERMA IM AND CLINE MJ. (1984). Expression of cellular oncogenes in human malignancies. Science, 224, 256-262.
24. SPANDIDOS DA AND KERR IB. (1984). Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum. Br. J. Cancer, 49, 681-688.
25. TASWELL C. (1981). Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol., 125, 1614-1619.
26. TSANG KY, NIERODA CA, DE FILIPPI R, CHUNG YK, YAMAUE H, GREINER JW AND SHLOM J. (1994). Induction of human cytotoxic T cell lines directed against point-mutated p21 rasderived synthetic peptides. Vaccine Res., 3, 183-193.